Jonathan H Watanabe

Title(s)Clinical Professor, Clinical Pharmacy Practice
SchoolSchool of Pharmacy and Pharmaceutical Sciences
Address101 Theory, Suite 100
Irvine CA 92697-3958
Phone(949) 824-0498
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Association of Pre-Pandemic Telehealth With Emergency Department and Telehealth Usage During the Pandemic. Sr Care Pharm. 2024 Mar 01; 39(3):105-112. Strand M, Watanabe JH. PMID: 38379135.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    2. Considerations on the Weight Loss-Associated Glucagon-like Peptide-1 Receptor Agonists for Older People. Sr Care Pharm. 2023 Dec 01; 38(12):493-496. Watanabe JH. PMID: 38041227.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022. J Am Pharm Assoc (2003). 2024 Jan-Feb; 64(1):133-138. Watanabe JH, Kwon J, Nan B, Reikes A. PMID: 37821008.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Exploring Concomitant Acetylcholinesterase Inhibitor and Overactive Bladder Anticholinergic Use and Risk of Hospitalization in Medicare and Dual-Eligible Medicare-Medicaid Populations in a Historic Database. Pharmacy (Basel). 2023 Sep 07; 11(5). Watanabe JH, Hoang T. PMID: 37736912; PMCID: PMC10514781.
      View in: PubMed   Mentions:
    5. Improving Care for Opioid Use Disorder in Nursing Facilities. Sr Care Pharm. 2023 08 01; 38(8):309-310. Watanabe JH. PMID: 37496169.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    6. Effectiveness of letermovir for cytomegalovirus prophylaxis in allogeneic hematopoietic stem cell transplant recipients: A global systematic review. J Am Pharm Assoc (2003). 2023 Jul-Aug; 63(4):1138-1149. Sepassi A, Saunders IM, Bounthavong M, Taplitz RA, Logan C, Watanabe JH. PMID: 37207713.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    7. Cost Effectiveness of Letermovir for Cytomegalovirus Prophylaxis Compared with Pre-Emptive Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients in the United States. Pharmacoecon Open. 2023 May; 7(3):393-404. Sepassi A, Saunders IM, Bounthavong M, Taplitz RA, Logan C, Watanabe JH. PMID: 36840894; PMCID: PMC10169956.
      View in: PubMed   Mentions: 3  
    8. The Critical Role of Pharmacists in Treating Older People in the Opioid Crisis. Sr Care Pharm. 2023 Feb 01; 38(2):47-49. Watanabe JH. PMID: 36751937.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    9. Minding the gap and the value of metrics: Count of working pharmacists in the United States. J Am Pharm Assoc (2003). 2023 May-Jun; 63(3):899-903. Hirsch JD, Nguyen MH, Abugazia J, Watanabe JH. PMID: 36631343.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. Responding to "Senior Care Pharmacists Must Be the Disruptive Force that Reduces Adverse Drug Events in Older People". Sr Care Pharm. 2022 09 01; 37(9):380-381. Khartabil N, Watanabe JH. PMID: 36039001.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    11. Federal and State Pharmacy Regulations and Dispensing Barriers to Buprenorphine Access at Retail Pharmacies in the US. JAMA Health Forum. 2022 08 05; 3(8):e222839. Qato DM, Watanabe JH, Clark KJ. PMID: 36218988.
      View in: PubMed   Mentions: 2     Fields:    
    12. Senior Care Pharmacists Must Be the Disruptive Force that Reduces Adverse Drug Events in Older People. Sr Care Pharm. 2022 07 01; 37(7):247-249. Watanabe JH. PMID: 35752921.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    13. Effects of financial toxicity on prescription drug use and mental well-being in cancer patients. Explor Res Clin Soc Pharm. 2022 Jun; 6:100136. Chan K, Sepassi A, Saunders IM, Goodman A, Watanabe JH. PMID: 35909716; PMCID: PMC9335927.
      View in: PubMed   Mentions: 2  
    14. Examination of Medication Use Patterns by Age Group, Comorbidity, and Month in COVID-19 Positive Patients in a Large Statewide Health System During the Pandemic in 2020. J Pharm Technol. 2022 Apr; 38(2):75-87. Watanabe JH, Kwon J, Nan B, Abeles SR, Mehta SR. PMID: 35571345; PMCID: PMC9096847.
      View in: PubMed   Mentions: 1  
    15. Risk of Negative Health Outcomes and High Costs for People With Diabetes and Unmet Psychological Needs in the United States. Diabetes Spectr. 2022; 35(2):207-215. Sepassi A, Bounthavong M, Singh RF, Heyman M, Beizai K, Watanabe JH. PMID: 35668883; PMCID: PMC9160558.
      View in: PubMed   Mentions:
    16. Transferring Key Success Factors from Ambulatory Care into the Community Pharmacy in the United States. Pharmacy (Basel). 2021 Jun 23; 9(3). Luli AJ, Awdishu L, Hirsch JD, Watanabe JH, Bounthavong M, Morello CM. PMID: 34201476; PMCID: PMC8293369.
      View in: PubMed   Mentions:
    17. Association of Age and Hospitalization Amongst Those with Underlying High-risk Conditions at COVID-19 Diagnosis in a Large, State-wide Health System. J Gen Intern Med. 2021 09; 36(9):2906-2908. Watanabe JH, Kwon J, Mehta SR. PMID: 34137004; PMCID: PMC8208375.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    18. When Can We Trust Real-World Data To Evaluate New Medical Treatments? Clin Pharmacol Ther. 2022 01; 111(1):24-29. Simon GE, Bindman AB, Dreyer NA, Platt R, Watanabe JH, Horberg M, Hernandez A, Califf RM. PMID: 33932030; PMCID: PMC9292968.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    19. When Can We Rely on Real-World Evidence to Evaluate New Medical Treatments? Clin Pharmacol Ther. 2022 01; 111(1):30-34. Simon GE, Platt R, Watanabe JH, Bindman AB, John London A, Horberg M, Hernandez A, Califf RM. PMID: 33895994; PMCID: PMC8251042.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    20. When Can Nonrandomized Studies Support Valid Inference Regarding Effectiveness or Safety of New Medical Treatments? Clin Pharmacol Ther. 2022 01; 111(1):108-115. Franklin JM, Platt R, Dreyer NA, London AJ, Simon GE, Watanabe JH, Horberg M, Hernandez A, Califf RM. PMID: 33826756; PMCID: PMC9291272.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    21. Medication Use Patterns in Hospitalized Patients With COVID-19 in California During the Pandemic. JAMA Netw Open. 2021 05 03; 4(5):e2110775. Watanabe JH, Kwon J, Nan B, Abeles SR, Jia S, Mehta SR. PMID: 34019090; PMCID: PMC8140369.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCellsPHPublic Health
    22. When Are Treatment Blinding and Treatment Standardization Necessary in Real-World Clinical Trials? Clin Pharmacol Ther. 2022 01; 111(1):116-121. Watanabe JH, Simon GE, Horberg M, Platt R, Hernandez A, Califf RM. PMID: 33829639; PMCID: PMC9290851.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    23. DISCARDED MEDICATIONS IN VIALS ARE A SYMPTOM OF OUR HEALTH CARE SYSTEM: A CALL TO ACTION. J Manag Care Spec Pharm. 2021 May; 27(5):689-690. Watanabe JH, Lieu T, Shortliffe EH. PMID: 33908281; PMCID: PMC10390907.
      View in: PubMed   Mentions:    Fields:    Translation:PHPublic Health
    24. Associations of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use with Colorectal Cancer Risk in the Women's Health Initiative. Cancer Epidemiol Biomarkers Prev. 2021 05; 30(5):1029-1032. Brasky TM, Flores KF, Larson JC, Newton AM, Shadyab AH, Watanabe JH, Lane DS, Thomson CA, LaCroix AZ. PMID: 33627382; PMCID: PMC8102324.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    25. Comparison of botulinum toxins for treatment of movement disorders: real-world utilization and cost analysis in a national Medicare population. J Manag Care Spec Pharm. 2021 Apr; 27(4):478-487. Kazerooni R, Watanabe JH. PMID: 33511895; PMCID: PMC10394205.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    26. Pharmacist-directed care to optimize medication use: a healthcare imperative in the United States. Expert Rev Pharmacoecon Outcomes Res. 2020 Oct; 20(5):419-421. Watanabe JH. PMID: 32902351.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    27. Association of combination opioid, benzodiazepine, and muscle relaxant usage with emergency department visits in a nationwide cohort in the United States. Int J Clin Pharm. 2021 Apr; 43(2):358-364. Watanabe JH, Yang J. PMID: 32266557.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    28. Pharmacists on the front-line of solving a public health crisis: Increasing access to medications for opioid use disorder. J Am Pharm Assoc (2003). 2020 Mar - Apr; 60(2):297-303. Luli AJ, Bounthavong M, Watanabe JH. PMID: 31889651.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    29. Hospitalization and Combined Use of Opioids, Benzodiazepines, and Muscle Relaxants in the United States. Hosp Pharm. 2020 Oct; 55(5):286-291. Watanabe JH, Yang J. PMID: 32999498; PMCID: PMC7502868.
      View in: PubMed   Mentions: 6  
    30. Advancing Pharmacist Collaborative Care within Academic Health Systems. Pharmacy (Basel). 2019 Oct 11; 7(4). Awdishu L, Singh RF, Saunders I, Yam FK, Hirsch JD, Lorentz S, Atayee RS, Ma JD, Tsunoda SM, Namba J, Mnatzaganian CL, Painter NA, Watanabe JH, Lee KC, Daniels CD, Morello CM. PMID: 31614555; PMCID: PMC6958419.
      View in: PubMed   Mentions: 9  
    31. Examining the Pharmacist Labor Supply in the United States: Increasing Medication Use, Aging Society, and Evolution of Pharmacy Practice. Pharmacy (Basel). 2019 Sep 19; 7(3). Watanabe JH. PMID: 31546891; PMCID: PMC6789639.
      View in: PubMed   Mentions: 2  
    32. Policy impact: When policy fails. Nurs Forum. 2020 Jan; 55(1):37-44. Davidson JE, Marshall MF, Watanabe JH. PMID: 31432541.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    33. Emergency Department Visits for Psychotropic-Related Adverse Drug Events in Older Adults With Alzheimer Disease, 2013-2014. Ann Pharmacother. 2019 12; 53(12):1173-1183. Sepassi A, Watanabe JH. PMID: 31342766.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    34. Anxiety and Depression Symptoms and Every-Night Sleep Medication Use in Older Adults. Sr Care Pharm. 2019 Jul 01; 34(7):449-455. Watanabe JH, Chau DL. PMID: 31383056.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    35. Anticoagulant Use in High Stroke-Risk Patients With Nonvalvular Atrial Fibrillation. Consult Pharm. 2018 Sep 01; 33(9):521-530. Nguyen HK, Humber D, Checkoway H, Blanchard D, Watanabe JH. PMID: 30185292.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    36. Federal and Individual Spending on the 10 Costliest Medications in Medicare Part D from 2011 to 2015. J Am Geriatr Soc. 2018 08; 66(8):1621-1624. Watanabe JH, Chau DL, Hirsch JD. PMID: 29972589.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    37. Cost of Prescription Drug-Related Morbidity and Mortality. Ann Pharmacother. 2018 09; 52(9):829-837. Watanabe JH, McInnis T, Hirsch JD. PMID: 29577766.
      View in: PubMed   Mentions: 100     Fields:    Translation:Humans
    38. Medication Regimen Complexity in Long-Term Care Facilities and Adverse Drug Events-Related Hospitalizations. Consult Pharm. 2017 May 01; 32(5):281-284. Tam SHY, Hirsch JD, Watanabe JH. PMID: 28483008.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    39. Medication Use, Falls, and Fall-Related Worry in Older Adults in the United States. Consult Pharm. 2016 Jul; 31(7):385-93. Watanabe JH. PMID: 27412315.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    40. An evaluation of health care expenditures in Crohn's disease using the United States Medical Expenditure Panel Survey from 2003 to 2013. Res Social Adm Pharm. 2017 May - Jun; 13(3):530-538. Bounthavong M, Li M, Watanabe JH. PMID: 27263802.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    41. Value of Information in Asia: Concepts, Current Use, and Future Directions. Value Health Reg Issues. 2016 May; 9:99-104. Dilokthornsakul P, McQueen RB, Chaiyakunapruk N, Spackman E, Watanabe JH, Campbell JD. PMID: 27881269.
      View in: PubMed   Mentions:    Fields:    
    42. Definition and Classification of Generic Drugs Across the World. Appl Health Econ Health Policy. 2015 Aug; 13 Suppl 1:S5-11. Alfonso-Cristancho R, Andia T, Barbosa T, Watanabe JH. PMID: 26091708; PMCID: PMC4519628.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    43. Approach to addressing missing data for electronic medical records and pharmacy claims data research. Pharmacotherapy. 2015 Apr; 35(4):380-7. Bounthavong M, Watanabe JH, Sullivan KM. PMID: 25884526.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    44. Association of increased emergency rooms costs for patients without access to necessary medications. Res Social Adm Pharm. 2015 Jul-Aug; 11(4):499-506. Watanabe JH, Ney JP. PMID: 25487421.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    45. Association of copayment with likelihood and level of adherence in new users of statins: a retrospective cohort study. J Manag Care Pharm. 2014 Jan; 20(1):43-50. Watanabe JH, Kazerooni R, Bounthavong M. PMID: 24372459; PMCID: PMC10437734.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    46. Association of polypharmacy and statin new-user adherence in a Veterans Health Administration population: a retrospective cohort study. Ann Pharmacother. 2013 Oct; 47(10):1253-9. Watanabe JH, Bounthavong M, Chen T, Ney JP. PMID: 24259688.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    47. Association of copayment and statin adherence stratified by socioeconomic status. Ann Pharmacother. 2013 Nov; 47(11):1463-70. Kazerooni R, Bounthavong M, Watanabe JH. PMID: 24259605.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    48. Association between statin adherence and cholesterol level reduction from baseline in a veteran population. Pharmacotherapy. 2013 Oct; 33(10):1044-52. Kazerooni R, Watanabe JH, Bounthavong M. PMID: 23744794.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    49. Cost-benefit analysis: intraoperative neurophysiological monitoring in spinal surgeries. J Clin Neurophysiol. 2013 Jun; 30(3):280-6. Ney JP, van der Goes DN, Watanabe JH. PMID: 23733093.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    50. Revisiting the medication possession ratio threshold for adherence in lipid management. Curr Med Res Opin. 2013 Mar; 29(3):175-80. Watanabe JH, Bounthavong M, Chen T. PMID: 23320610.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    51. Cost-effectiveness of intraoperative neurophysiological monitoring for spinal surgeries: beginning steps. Clin Neurophysiol. 2012 Sep; 123(9):1705-7. Ney JP, van der Goes DN, Watanabe JH. PMID: 22386320.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    52. Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: Post hoc analysis of pooled data from two randomized, placebo-controlled trials. Drugs Aging. 2011 Feb 01; 28(2):151-60. Sand PK, Rovner ES, Watanabe JH, Oefelein MG. PMID: 21275440.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    53. Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder. Urology. 2010 Oct; 76(4):835-40. Watanabe JH, Campbell JD, Ravelo A, Chancellor MB, Kowalski J, Sullivan SD. PMID: 20430422.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans